Medical Devices◆
AccuVein
Transforming intravenous delivery.
Handheld vein illumination, now in use in thousands of hospitals worldwide.
We invest because we
choose to.
A private direct-investment syndication platform for family offices and a small circle of long-tenured investors. No blind pool. Minimal overhead and radically efficient execution. Only conviction in the founders rebuilding medicine.
01 Philosophy
Not a fund. A platform.
Private Medical Equity is a direct-investment syndication platform. We bring a curated circle of family offices and high-net-worth investors alongside us, deal by deal, on equal terms.
We did not raise a billion-dollar fund obligated to deploy. We are not paid to be busy. We invest because a deal earns it, and because we believe in the people building it.
I
Direct, not pooled.
Every investment is its own syndicate. Our investors choose what they own, deal by deal.
II
Aligned, not extractive.
Minimal overhead and radically efficient execution. We earn alongside our investors, on the same terms.
III
Conviction, not mandate.
We invest because we have spent our careers waiting for the rare opportunity in front of us.
02 Diligence & Deal Partners
Investors and clinicians who have built what we back.
Our diligence and deal partners are accomplished healthcare investors and clinical experts with direct operating, medical and life-science venture backgrounds. They have founded companies, led clinical programs, and underwritten investments that have defined entire categories.
Every opportunity is reviewed by a working group of practising clinicians and senior investors before a single dollar is syndicated to the platform.
Clinical authority.
Practicing surgeons, interventional cardiologists, ophthalmologists, and oncologists who evaluate the science and the standard of care before we engage.
Operating record.
Former founders and executives of FDA-cleared device, therapeutics, and diagnostics companies with successful exits to global strategics.
Venture pedigree.
Decades of life-science venture and growth-stage investing across leading healthcare funds, with realized returns across multiple cycles.
03 Selected Investments
A preview of past investments.
A representative selection from past syndications. Current opportunities and the full portfolio are reserved for members of the platform.
Therapeutics◆
BioCanCell
Transforming cancer therapy.
Targeted gene therapy platform advancing late-stage clinical programs in bladder cancer.
Acquired by Chemomab (2021)
Pharmaceutical Delivery◆
Eyenovia
Next-generation high-precision piezo-print eye pharmaceuticals.
Microdose dispensing redefining the topical ophthalmic standard.
IPO (2018)
Surgical Devices◆
IanTech
Next-generation interventional technology for cataract surgery.
Acquired by a global ophthalmic leader.
Acquired by Carl Zeiss Meditec (2018)
Surgical Robotics◆
Preceyes Robotics
Next-generation micro-precision robotics.
The first robotic system to perform sub-retinal surgery in humans.
Acquired by Carl Zeiss Meditec (2022)
Neuromodulation◆
Noctrix Health
Next-generation neuromodulation for chronic neurologic disease.
Wearable neuromodulation device for restless leg syndrome.
Acquired by ResMed (2026)
Neonatal Care◆
Novonate
Transforming neonatal ICU care.
Medical device revolutionizing umbilical catheter protection and securement.
Acquired by Laborie (2023)
Ophthalmology◆
Iantrek, Inc.
Next-generation bio-interventional treatments for glaucoma.
Advancing a new class of restorative interventions for the glaucoma surgeon.
Past performance is not indicative of future results. Investments shown are illustrative of our focus and do not represent the platform's complete record.
04 Approach
We find the deal. We lead or co-invest. We bring our trusted syndicate along.
Sourced, not solicited.
Most of what we invest in is found through relationships built over twenty years with clinicians, founders, scientists, and the operators they trust.
Concentrated by design.
Three to five new syndications per year. Each receives the full attention of a partner and the operating group around them.
Quietly held.
We invest with patience and discretion. Our investors expect privacy; our companies depend on it.
05 The Platform
A small group. A long horizon.
Private Medical Equity was founded by a small group of operators and clinicians who wanted a different kind of platform. One without the obligation to deploy, and with the freedom to wait for the right opportunity.
We remain founder-owned, independent, and accountable to a single circle of long-tenured investors.
“We do not invest to be in the market. We do not invest because we need to deploy capital or race against the timelines of a fundraising reality. We invest because we find great stories and opportunities that resonate with our investment thesis.”
“We are not in the business of chasing allocations. We invest alongside founders we believe in, in companies we understand deeply, and only when the science, the team, and the moment align.”
06 Contact
Most of what we do is behind the door.
Members of the platform access live opportunities, diligence materials, and portfolio updates through the private investor area. New introductions are made by referral.
partners@privatemedicalequity.comNew York
295 Madison Avenue, New York, NY 10017